FDA OKs label update for etravirine
FDA has approved a label update to include a 200-mg formulation of etravirine (Intelence, Tibotec Therapeutics), a non-nucleoside reverse transcriptase inhibitor indicated for the treatment of HIV-1 in adults resistant to an NNRTI and other antiretroviral agents.
FDA has approved a label update to include a 200-mg formulation of etravirine (Intelence, Tibotec Therapeutics), a non-nucleoside reverse transcriptase inhibitor (NNRTI) indicated for the treatment of HIV-1 in adults resistant to an NNRTI and other antiretroviral (ARV) agents.
The recommended oral dose of etravirine tablets is 200 mg (one 200-mg tablet or two 100-mg tablets) taken twice a day following a meal. The new 200-mg product formulation is expected to launch in the United States sometime this month. The 100-mg tablet will remain available.
Patients who are unable to swallow etravirine tablets whole may disperse the tablets in a glass of water.
Novo Nordisk Terminates Collaboration with Hims & Hers
June 23rd 2025The FDA had resolved the shortage of Wegovy in April, and telehealth providers were advised to stop selling compounded semaglutide products. Novo Nordisk said that Hims & Hers continues to offer these compounded drugs.
Read More
